Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) On August 10, 2021, Wave Life Sciences Ltd. (the "Company") held its 2021


    Annual General Meeting of Shareholders (the "Annual Meeting"). Of the
    50,770,379 ordinary shares issued and outstanding and eligible to vote as of
    the meeting date of August 10, 2021, a quorum of 37,018,397 ordinary shares,
    or 72.91%, of the eligible shares, was present in person or represented by
    proxy at the Annual Meeting.

(b) The following actions were taken at the Annual Meeting, all of which are


    described in the Company's definitive proxy statement that was filed with the
    Securities and Exchange Commission on June 28, 2021 (the "Proxy Statement").
    The final voting results for each of the proposals voted upon at the Annual
    Meeting are set forth below.

Proposal 1 (a) - (i)- Shareholders re-elected nine of the Company's existing directors to the Board of Directors for a term ending on the Company's 2022 Annual General Meeting of Shareholders and his or her successor is duly elected and qualified, with the final votes cast as follows:





                                                                             Broker
Board of Directors Nominee       For            Against       Abstain       Non-Vote
Paul B. Bolno, M.D., MBA       33,864,224          59,438        8,719       3,086,016
Mark H.N. Corrigan, M.D.       33,839,396          82,609       10,376       3,086,016
Christian Henry                33,805,843         117,883        8,655       3,086,016
Peter Kolchinsky, Ph.D.        30,135,326       3,787,809        9,246       3,086,016
Adrian Rawcliffe               33,843,584          79,946        8,851       3,086,016
Ken Takanashi                  32,012,104       1,912,341        7,936       3,086,016
Aik Na Tan                     33,849,642          73,099        9,640       3,086,016
Gregory L. Verdine, Ph.D.      33,874,350          49,556        8,475       3,086,016
Heidi L. Wagner, J.D.          33,859,985          65,319        7,077       3,086,016

Proposal 2- Shareholders re-appointed KPMG LLP to serve as the Company's independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2022, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of the Company's 2022 Annual General Meeting of Shareholders, with the final votes cast as follows:





   For       Against   Abstain   Broker Non-Vote
37,004,199    9,831     4,367           0

Proposal 3- Shareholders approved the Company's payment of cash and equity-based compensation to the Company's non-employee directors for their service on the Board of Directors and its committees (including payment in arrears to the Research and Development Committee for service for the period of January 1, 2021 through the date of the Annual Meeting and payments relating to withholding taxes to be paid to the U.S. Internal Revenue Service on behalf of one of our ex-U.S. Directors), in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:





   For       Against   Abstain   Broker Non-Vote
33,850,944   69,846    11,591       3,086,016

Proposal 4- Shareholders approved the Company's 2021 Equity Incentive Plan, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:





   For        Against    Abstain   Broker Non-Vote
29,929,337   3,994,580    8,464       3,086,016

--------------------------------------------------------------------------------

Proposal 5- Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the manner and on the basis set forth in the Proxy Statement, with the final votes cast as follows:





   For       Against   Abstain   Broker Non-Vote
33,821,187   107,981    3,213       3,086,016

Proposal 6- Shareholders approved on a non-binding, advisory basis only, the compensation of our named executive officers, in the manner and on the basis set forth described in the proxy statement, with the final votes cast as follows:





   For       Against   Abstain   Broker Non-Vote
33,669,973   249,754   12,654       3,086,016

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses